Comparison of the safety and clinical efficacy of glucagonlike peptide-1 receptor agonist and α-glucosidase inhibitor among Chinese people with type 2 diabetes.

Purpose: To compare the safety and efficacy of once-weekly prescription of GLP-1 receptor agonists (adlyxin) with those of α-glucosidase inhibitor (voglibose) and other reference drugs (RD). Methods: A total of 1250 stable diabetes-mellitus patients from the Department of Endocrinology, Ningbo No. 6 Hospital, Ningbo, Zhejiang 315040, China were enrolled in this study between Feb 2018 and Jan 2020. They were treated using physical exercise and diet chart therapy. The patients were assigned to three different groups and administered GLP-1 receptor agonist (GLP-1RA) or glucosidase inhibitor (voglibose) and other reference drugs (RDs). The safety and efficacy of these drugs were compared. The primary endpoint was the number of treatment-emergent adverse events (TEAEs), while the secondary endpoints were based on symptomatic hypoglycaemic episodes and other biochemical parameters. Results: Patients who used α-glucosidase inhibitors had the highest percentage of TEAEs, when compared to those on GLP-1RAs and RDs (p < 0.05). No specific cases of severe hypoglycaemia were observed among all the groups. Users of adlyxin also achieved significant glycaemic control at the end of the study period, when compared to voglibose users, with a mean HbA1c baseline of 8.2 % (p < 0.05). Conclusion: These results indicate that the GLP-1 receptor agonist adlyxin achieved good glycaemic control. Thus, it has beneficial potential for use among type 2 diabetes in the Chinese population. [ABSTRACT FROM AUTHOR]